



Armetheon to Participate in the Hume Brophy 7th Annual Healthcare Conference

Milpitas, CA, October 8, 2015 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Dr. Sanjay Kakkar, Chief Executive Officer, will serve as a panelist at the Hume Brophy 7th Annual Healthcare Conference on Thursday, October 15, 2015 at 3:30pm BST in London, United Kingdom.

Dr. Kakkar will participate on the panel titled “Changing Business Models: What models will be most successful? Platforms, hybrids, service models, re-purposed assets?” The panel will discuss and debate trends in business models to evaluate which are working well now and why, as well as which might work in the future as the healthcare business environment evolves.

About Armetheon

Armetheon, Inc., is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis. Armetheon focuses on improved therapies with the goal of increased efficacy, safety, and utility, targeting specialty markets with clearly defined regulatory pathways. Armetheon's lead candidate, tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for the prevention and management of thrombosis. For more information: www.armetheon.com.

Contacts

For Armetheon:
Heather Lake, Director of Corporate Development
+1 650-646-3898, ext. 121
hlake@armetheon.com

For Media: Justin Jackson
For Investor Inquiries: Ami Bavishi
Burns McClellan
+1 212-213-0006
jjackson@burnsmc.com
abavishi@burnsmc.com